Sun Pharma announces trading window closure ahead of Q2 results

Sun Pharmaceutical Industries Limited announced the closure of its trading window for dealing in company shares, effective October 1, 2025. This closure is in accordance with the company's Code of Conduct for Prohibition of Insider Trading and will remain in effect until 48 hours after the declaration of the unaudited financial results for the quarter and half year ended September 30, 2025. The company will communicate the date of the board meeting to consider and approve these results in due course.

The announcement, dated September 22, 2025, was issued by Anoop Anjanikumar Deshpande, company secretary and compliance officer. Sun Pharmaceutical Industries Limited is listed on the National Stock Exchange of India and BSE Limited.

The company's registered office is located at SPARC, Tandalja, Vadodara, Gujarat, INDIA, with its corporate office in Mumbai. The closure ensures compliance with insider trading regulations, preventing misuse of unpublished price-sensitive information by designated persons during the financial reporting period.